These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7793872)

  • 1. Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia.
    Chidiac C; Roussel-Delvallez M; Guery B; Beaucaire G
    Antimicrob Agents Chemother; 1995 Mar; 39(3):677-9. PubMed ID: 7793872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin].
    Soussy CJ; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1990 May; 38(5):376-84. PubMed ID: 2367152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of piperacillin/quinolone combinations].
    Soussy CJ; Leclercq R; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):357-60. PubMed ID: 3136421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
    Soussy CJ; Deforges L; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current status of resistance of bacteria to pefloxacin in hospital units. Cross resistance with ofloxacin and ciprofloxacin. Results of a multicenter study].
    Thabaut A; Meyran M; Fabre R; Dellamonica P; Moreau N
    Pathol Biol (Paris); 1994 May; 42(5):369-74. PubMed ID: 7824298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
    Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
    Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.
    Join-Lambert OF; Michéa-Hamzehpour M; Köhler T; Chau F; Faurisson F; Dautrey S; Vissuzaine C; Carbon C; Pechère J
    Antimicrob Agents Chemother; 2001 Feb; 45(2):571-6. PubMed ID: 11158756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activity of fluoroquinolones studied on a model of suppurative meningoencephalitis caused by Pseudomonas aeruginosa in mice].
    Padeĭskaia EN; Mnatsakanian VE
    Antibiot Khimioter; 1991 Jul; 36(7):25-8. PubMed ID: 1953184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
    Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2503-10. PubMed ID: 8585734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of 4-quinolones against Pseudomonas aeruginosa.
    Morissey I; Smith JT
    Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.
    Torres BGS; Helfer VE; Bernardes PM; Macedo AJ; Nielsen EI; Friberg LE; Dalla Costa T
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
    Yagel SK; Barrett JF; Amaratunga DJ; Frosco MB
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2894-7. PubMed ID: 9124863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
    Vitkauskiene A; Sakalauskas R; Dudzevicius V
    Medicina (Kaunas); 2003; 39(3):254-9. PubMed ID: 12695638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
    Aubert G; Pozzetto B; Dorche G
    J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin.
    López-Rojas R; Sánchez-Céspedes J; Docobo-Pérez F; Domínguez-Herrera J; Vila J; Pachón J
    Int J Antimicrob Agents; 2011 Oct; 38(4):355-9. PubMed ID: 21820876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Community-acquired Pseudomonas aeruginosa bacteremic pneumonia in a "healthy" subject].
    Illinger J; Mohammedi I; Martin O; Argaud L; St Denis M; Robert D
    Presse Med; 2003 Jul; 32(24):1123. PubMed ID: 12947742
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro antibacterial activity of a new fluoroquinolone, fleroxacin as a function of the sensitivity or resistance to nalidixic acid and to pefloxacin].
    Soussy CJ; Leclercq R; Deforges L; Duval J
    Pathol Biol (Paris); 1989 May; 37(5):364-9. PubMed ID: 2506511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.